Biotechnologia Acta

ISSN 2410-776X (Online),
ISSN 2410-7751 (Print)

Biotechnologia Acta
V. 8, No 3, 2015

Biotechnologia Acta V. 8, No 3, 2015
DOI: 10.15407/biotech8.03.095
Р. 95-103, Bibliography , English
Universal Decimal Classification: 579.864.1:615.331

ANTIBACTERIAL ACTIVITY OF Lactobacillus casei IMV B-7280 IN CASES OF EXPERIMENTAL UROGENITAL STAPHYLOCOCCAL INFE

Babenko L. P.¹, Lazarenko L. M.¹, Demchenko Z. K.¹, Konarbaeva O. A.², Veccio G. Lo³, Spivak M. Ja.¹

¹Zabolotny Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine, Kyiv
²Auezov South Kazakhstan state University, Shymkent, Republic of Kazakhstan
³Stucom Centre of the Studies, Barcelona, Spain

The aim of work was to determine antibacterial activity of Lactobacillus casei ІМV В-7280 probiotic strain on the experimental urogenital tract infection of mice. The influence of intravaginal and/or per os administration of this strain once per day during 7 days on the microflora of vagina, kidneys and intestinal contents of Staphylococcus aureus 8325-4 infected mice was studied.

It was established, that in cases of experimental staphylococcal infection of urogenital tract L. Casei IMV B-7280 had effective antagonistic activity against S. aureus 8325-4 and opportunistic bacteria. After L. casei IMV B-7280 introduction into infected mice reduction or complete elimination of S. aureus 8325-4 in vagina, kidneys and intestinal contents in different periods of observation was established. Under the influence of L. casei ІМВ В-7280 the number of coliform bacteria, streptococci and staphylococci in the vagina was normalized, and fungal flora — decreased even in comparison with intact mice. Normalization of kidneys microflora was also observed. In the intestinal contents of infected mice trea ted with L. casei IMV B-7280 the number of streptococci did not change, staphylococci number decreased, but the number of fungal and coliform flora remained relatively low during the observation period.

L. casei IMV B-7280 probiotic strain is promising to create immunobiotics with antibacterial action, which can be used for the prevention and treatment of urogenital infections caused by opportunistic microorganisms.

Key words: antibacterial activity, immunobiotics, Lactobacillus casei, Staphylococcus aureus.

© Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, 2008

• References

  • 1. Foxman B. Epidemiology of Urinary Tract Infections: incidence, morbidity, and economic costs. Am. J. Med. 2002, V. 113 (Issue 1), P. 5–13.
    http://dx.doi.org/10.1016/S0002-9343(02)01054-9

    2. Koumans E. H., Sternberg M., Bruce C., McQuillan G., Kendrick J., Sutton M., Markowitz L. E. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex. Transm. Dis. 2007, 34 (11), 864–869.
    http://dx.doi.org/10.1097/OLQ.0b013e318074e565

    3. Srinivasan S., Fredricks D. N. The human vaginal bacteria biota and bacterial vaginosis. Interdiscip. Perspect. Infect. Dis. 2009, 2008; 2008:750479.
    doi: 10.1155/2008/750479.

    4. Yakovenko L. F., Sidorik L. L., Romashchenko O. V., Rudenko A. V., Shcherbak M. O., Obukhova I. A., Lazarenko L. M., Spivak M. Ya. The diagnostic significance of indicators of  immunity in women with chronic inflammatory diseases of the pelvic organs. Zdorovia Ukrainy. 2012, 3 (7), 15–20. (In Ukrainian).

    5. Gupta K., Scholes D., Stamm W. E. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999, 281 (8), 736–738.
    http://dx.doi.org/10.1001/jama.281.8.736

    6. Reid G., Bruce A. W. Urogenital infections in women: can probiotics help? Postgrad. Med. J. 2003,79 (934), 428–432.http://dx.doi.org/10.1136/pmj.79.934.428

    7. Marelli G., Papaleo E., Ferrari A. Lactobacilli for prevention of urogenital infections: a review.  Eur. Rev. Med. Pharmacol. Sci. 2004, 8 (20), 87–95.

    8. Foster L. M., Tompkins T. A., Dahl W. J. A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011. Benefic. Microb. 2011, 2 (40), 319–334.
    http://dx.doi.org/10.3920/BM2011.0032

    9. Lazarenko L., Babenko L., Sichel L., Pidgorskyi V., Mokrozub V., Voronkova O., Spivak M. Аntagonistic Action of Lactobacilli and Bifidobacteria in Relation to Staphylococcus aureus and Their Influence on the Immune Response in Cases of Intravaginal Staphylococcosis in Mice. Probiot. Antimicrob. Prot. 2012, 4 (2), 78–89.

    10. Kitazawa H., Villena J., Alvarez S. Probiotics: immunobiotics and immunigenenics. USA.: CRC Press. 2014, 402 p.

    11. Reid G. The scientific basis for probiotic strains of Lactobacillus. Appl. Environ. Microbiol. 1999, 65 (9), 3763–3766.

    12. McGroarty J. A., Reid G. Detection of a Lactobacillus substance that inhibits Escherichia col. Can. J. Microbiol. 1988, 34 (80), 974–978.
    http://dx.doi.org/10.1139/m88-171

    13. Reid G., Bruce A. W. Selection of lactobacillus strains for urogenital probiotic applications. J. Infect. Dis. 2001, 183 (Suppl 1), 77–80.
    http://dx.doi.org/10.1086/318841

    14. Osset J., Bartolome R. M., Garcia E., Andreu A. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J. Infect. Dis. 2001, 183 (30), 485–491.
    http://dx.doi.org/10.1086/318070

    15. Gardiner G. E., Heinemann C., Bruce A. W., Beuerman D., Reid G. Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rham nosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin. Diagn. Lab. Immunol. 2002, 9 (1), 92–96.

    16. De Vrese M., Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 2008, V. 111, P. 1–66.
    doi: 10.1007/10_2008_097.

    17. Kovachev S., Dobrevski-Vacheva R. Effect of Lactobacillus casei var rhamnosus (Gynophilus) in restoring the vaginal flora by female patients with bacterial vaginosis-randomized, open clinical trial. Akush. Ginekol. (Sofiia). 2013, V. 52 (Suppl 1), P. 48–53. (In Bulgarian).

    18. Bruce A. W., Reid G. Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections. Can. J. Microbiol. 1988, 34 (3), 339–343.
    http://dx.doi.org/10.1139/m88-062

    19. Reid G., Bruce A. W., Fraser N., Heinemann C., Owen J., Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol. Med. Microbiol. 2001, 30 (10), 49–52.
    http://dx.doi.org/10.1111/j.1574-695X.2001.tb01549.x

    20. Falagas M. E., Betsi G. I., Tokas T., Athanasiou S. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs. 2006, 66 (90), 1253–1261.
    http://dx.doi.org/10.2165/00003495-200666090-00007

    21. Spivak M. Ya., Shinkarenko L. M., Pidgorskyi V. S., Gorchakov D. Yu., Starovoitova S. O., Lazarenko L. M., Timoshok N. O. The strain Lactobacillus casei IMV B-7280 — late interferon inducer and activator of macrophages.  Ukraina. Patent N 93133. 10.01.2011. (In Ukrainian).

    22. Starovoitova S. A., Lazarenko L. N., Avdieieva L. V., Polishchuk E. I., Timoshok N. O., Shinkarenko L. M., Babenko L. P., Mokrozub V. V., Spivak M. Ya., Cheipesh A. V., Nikolaichuk V. I. Search of Lactobacillus and Bifidobacterium genera strains promising for probiotics creation. Nauk. visnyk Uzhgorod. un-ty (Ser. Biol.). 2009, V. 26, P. 216–219. (In Russian).

    23. Postnikova E. A., Efimov B. A., Volodin N. N., Kafarskaja L. I. The search for promising strains of bifidobacteria and lactobacilli for the development of new biological products.  J. microbiol. 2004, V. 2, P. 64–69. (In Russian).

    24. Brilis V. I., Brilene T. A., Lencner H. P., Lencner A. A. Metodika izuchenija adgezivnogo processa mikroorganizmov.  Lab. work. 1986, V. 4, P. 210–212. (In Russian).

    25. Lazarenko L. Babenko L., Shynkarenko-Sichel L., Pidgorskyi V., Mokrozub V., Voronkova O., Spivak M. Antagonistic action of lactobacilli and bifidobacteria in relation to Staphylococcus aureus and their influence on the immune response in cases of intravaginal Staphylococcosis in mice. Probiot. Antimicrob. Prot. 2012, 4 (2), 78–89.
    http://dx.doi.org/10.1007/s12602-012-9093-z

    26. Z?rate G., Santos V., Nader-Macias M. E. Protective effect of vaginal Lactobacillus paracasei CRL 1289 against urogenital infection produced by Staphylococcus aureus in a mouse animal model. Infect. Dis. Obstet. Gynecol. 2007; 2007: 48358.
    doi: 10.1155/2007/48358.

    27. Chmielewska A., Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J. Gastroenterol. 2010, 16 (1), 69–75.

    28. Cross M. L., Ganner A., Teilab D., Fray L. M. Patterns of cytokine induction by grampositive and gram-negative probiotic bacteria. FEMS Immunol. Med. Microbiol. 2004, 42 (2), 173–180.
    http://dx.doi.org/10.1016/j.femsim.2004.04.001